• US Preventive Services Task Force, Douglas K Owens, Karina W Davidson, Alex H Krist, Michael J Barry, Michael Cabana, Aaron B Caughey, Chyke A Doubeni, John W Epling, Martha Kubik, C Seth Landefeld, Carol M Mangione, Lori Pbert, Michael Silverstein, Melissa A Simon, Chien-Wen Tseng, and John B Wong.
• Veterans Affairs Palo Alto Health Care System, Palo Alto, California.
• JAMA. 2020 Feb 25; 323 (8): 757-763.

ImportanceDementia (also known as major neurocognitive disorder) is defined by a significant decline in 1 or more cognitive domains that interferes with a person's independence in daily activities. Dementia affects an estimated 2.4 to 5.5 million individuals in the United States, and its prevalence increases with age.ObjectiveTo update its 2014 recommendation, the US Preventive Services Task Force (USPSTF) commissioned a review of the evidence on screening for cognitive impairment, including mild cognitive impairment and mild to moderate dementia, in community-dwelling adults, including those 65 years or older residing in independent living facilities.PopulationThis recommendation applies to community-dwelling older adults 65 years or older, without recognized signs or symptoms of cognitive impairment.Evidence AssessmentThe USPSTF concludes that the evidence is lacking, and the balance of benefits and harms of screening for cognitive impairment cannot be determined.RecommendationThe USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for cognitive impairment in older adults. (I statement).

14 keywords...

hide…